MindWalk Holdings Corp. (HYFT) stock
Close on Nov 12, 2026Market cap $46.71MP/E –Yield –
MindWalk Holdings Corp. grew revenue 43.4% to C$16.23M over the twelve months to Jul 31, 2026. Free cash flow was -C$12.49M. At the latest close the market valued the company at C$65.89M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 31, 2026
Valuation
- Market cap
- C$65.89M
- P/E ratio
- –
- Price to sales
- 4.06
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -18.95%
Fundamentals
- Revenue
- C$16.23M
- Free cash flow
- -C$12.49M
- Diluted shares
- 47M
Trading
- Previous close
- $1.03
- Open
- $1.03
- Day's range
- $0.96 – $1.03
- Volume
- 223,209
- Average volume (20 days)
- 240,132
- Beta (5 years)
- 1.37
- RSI (14 days)
- 33.3
- Volatility (1 year)
- 88.9%
- Relative volume
- 0.95×
- WACC
- 11.7%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | HYFT | S&P 500 | Difference | HYFT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -28.6% | -2.7% | −25.9 pts | ||
| 3 months | -23.7% | -1.7% | −21.9 pts | ||
| Year to date | -45.1% | +11.9% | −56.9 pts | ||
| 1 year | -44.1% | +12.0% | −56.1 pts | ||
| 3 years | -35.9% | +78.2% | −114.1 pts | -13.8% | +21.2% |
| 5 years | -83.3% | +73.2% | −156.5 pts | -30.1% | +11.6% |
| 10 years | +15284.6% | +309.6% | +14975.0 pts | +65.5% | +15.1% |
Eight years at a glance
Fiscal years 2019 to 2026 and trailing twelve months, CAD
Revenue
Gross profit
EPS, diluted
Free cash flow
Press releases
Releases MindWalk filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About MindWalk
Pharmaceutical Preparations
MindWalk Holdings Corp. is a biotechnology company focused on therapeutic antibody discovery and development, biocomputing, and artificial intelligence-driven biological research. The company operates through its subsidiaries, including BioStrand and ImmunoPrecise Antibodies, providing contract research services, custom antibody generation, protein production, and cryostorage solutions. Its offerings also incorporate proprietary platforms and computational tools designed to support biomedical workflows. MindWalk serves clients across the pharmaceutical, biotechnology, and academic research sectors.
Company profile, executives and historyMindWalk stock: common questions
What is MindWalk's stock price?
HYFT closed at $1.00 on Nov 12, 2026, down 2.91% on the day.
What is MindWalk's market cap?
MindWalk was worth $46.71M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
How much revenue does MindWalk make?
MindWalk reported revenue of C$16.23M for the twelve months to Jul 31, 2026, up 43.4% from a year earlier.
Does MindWalk pay a dividend?
No. MindWalk has not paid a cash dividend over the last twelve months.
How has HYFT stock performed over the past year?
Including dividends, HYFT returned -44.1% over the past year, against +12.0% for the S&P 500.
Who are MindWalk's competitors?
Companies most similar to MindWalk by business, industry and size include CELU, IMMP, BHST, PRQR, ISCO.
See a number that looks wrong?